Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Issued Folate Binding Protein (FBP) Cancer Vaccine Patent in Japan

Folate Binding Protein Phase 1/2 trial on track for results in 2013. Composition of Matter and Treatment patent covers Folate Binding Protein (FBP) peptide variants for individual or expanded...
July 18, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Issued NeuVax(TM) U.S. Patent

Patent strengthens NeuVax Intellectual Property position for treating Phase 3 target population of low-to-intermediate (IHC 1+/2+) HER2 patients. Provides NeuVax exclusivity for this...
June 18, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the 2012 BIO International Convention

LAKE OSWEGO, Ore., June 18, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
June 13, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Marcum Microcap Conference

LAKE OSWEGO, Ore., June 13, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
June 05, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces NeuVax(TM) (E75) Improves Disease-Free Survival at 60-Month Median Follow-Up

The combined SN-33 (Node Positive) (n=97) and SN-34 (Node Negative) (n=90) Intent-to-treat (ITT) population (n=187) continued to demonstrate an excellent safety and efficacy profile. Phase 2...
June 04, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents NeuVax Phase 1/2 Boosters Improve Disease-Free Survival at 60-Month Median Follow-Up

Booster inoculations are well-tolerated and appear to maintain long-term peptide-specific immunity and reduce disease recurrence rates Booster inoculations are included in the ongoing Phase 3...
May 31, 2012 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Adds Oncology Expert Dr. Gabriel Hortobagyi to Its Scientific Advisory Board

LAKE OSWEGO, Ore., May 31, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
May 14, 2012 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports First Quarter 2012 Financial Results

LAKE OSWEGO, Ore., May 14, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
May 10, 2012 07:10 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Expansion of Scientific Advisory Board

LAKE OSWEGO, Ore., May 10, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
May 10, 2012 06:55 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Notified That RXi Pharmaceuticals' Common Stock to Commence Trading Under Ticker Symbol "RXII"

LAKE OSWEGO, Ore., May 10, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...